ES2749009T3 - Inhibidores espirocíclicos de Catepsina C - Google Patents

Inhibidores espirocíclicos de Catepsina C Download PDF

Info

Publication number
ES2749009T3
ES2749009T3 ES15757523T ES15757523T ES2749009T3 ES 2749009 T3 ES2749009 T3 ES 2749009T3 ES 15757523 T ES15757523 T ES 15757523T ES 15757523 T ES15757523 T ES 15757523T ES 2749009 T3 ES2749009 T3 ES 2749009T3
Authority
ES
Spain
Prior art keywords
formula
compound
pharmaceutically acceptable
solvates
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15757523T
Other languages
English (en)
Spanish (es)
Inventor
Viktor Vintonyak
Matthias Grauert
Marc Grundl
Alexander Pautsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2749009T3 publication Critical patent/ES2749009T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES15757523T 2014-09-12 2015-09-08 Inhibidores espirocíclicos de Catepsina C Active ES2749009T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14184613 2014-09-12
PCT/EP2015/070449 WO2016038007A1 (en) 2014-09-12 2015-09-08 Spirocyclic inhibitors of cathepsin c

Publications (1)

Publication Number Publication Date
ES2749009T3 true ES2749009T3 (es) 2020-03-18

Family

ID=51535355

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15757523T Active ES2749009T3 (es) 2014-09-12 2015-09-08 Inhibidores espirocíclicos de Catepsina C

Country Status (34)

Country Link
US (3) US9540373B2 (enExample)
EP (2) EP3191487B1 (enExample)
JP (2) JP2017526716A (enExample)
KR (1) KR102510588B1 (enExample)
CN (2) CN108047240B (enExample)
AP (1) AP2017009733A0 (enExample)
AU (1) AU2015314355B2 (enExample)
BR (1) BR112017003433B1 (enExample)
CA (1) CA2960916C (enExample)
CL (1) CL2017000432A1 (enExample)
CO (1) CO2017002268A2 (enExample)
CY (1) CY1123033T1 (enExample)
DK (1) DK3191487T3 (enExample)
EA (1) EA031376B1 (enExample)
ES (1) ES2749009T3 (enExample)
HK (1) HK1255362A1 (enExample)
HR (1) HRP20191756T1 (enExample)
HU (1) HUE047208T2 (enExample)
IL (1) IL250262B (enExample)
LT (1) LT3191487T (enExample)
MX (2) MX367316B (enExample)
MY (1) MY188382A (enExample)
NZ (1) NZ728684A (enExample)
PE (1) PE20170438A1 (enExample)
PH (1) PH12017500453B1 (enExample)
PL (1) PL3191487T3 (enExample)
PT (1) PT3191487T (enExample)
RS (1) RS59444B1 (enExample)
SA (1) SA517381064B1 (enExample)
SG (1) SG11201701633SA (enExample)
SI (1) SI3191487T1 (enExample)
TW (1) TWI687424B (enExample)
UA (1) UA118610C2 (enExample)
WO (1) WO2016038007A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116282A2 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nicotinic acetylcholine receptor agonists
NO2699580T3 (enExample) 2014-01-24 2018-02-24
JP6529575B2 (ja) * 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
CN108047240B (zh) * 2014-09-12 2020-08-04 勃林格殷格翰国际有限公司 组织蛋白酶c的螺环化合物抑制剂
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
WO2018162312A1 (en) * 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
KR20200118103A (ko) * 2018-02-07 2020-10-14 인스메드 인코포레이티드 Anca 관련 혈관염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
HRP20250115T1 (hr) 2018-03-01 2025-05-23 Astrazeneca Ab Farmaceutski pripravci koji sadrže (2s)-{(1s)-1-cijano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil} -1,4-oksazepan-2-karboksamid
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN110256429B (zh) * 2019-06-17 2021-06-22 广东药科大学 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用
CN110257504A (zh) * 2019-06-30 2019-09-20 中南大学 一种难治性哮喘检测标记物的筛选方法及其应用
EP4182700A4 (en) 2020-07-20 2024-11-13 Insmed Incorporated METHODS FOR EXTRACTING NEUTROPHIL SERINE PROTEASES AND TREATMENT OF DIPETIDYL PEPTIDASE-1-MEDIATED DISEASES
CN114106005B (zh) * 2020-08-26 2025-08-01 西藏海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
EP4247490A2 (en) * 2020-11-17 2023-09-27 Vertex Pharmaceuticals Incorporated Solid forms of 4-(5-(4-fluorophenyl)-6-tetrahydro-2h-pyran-4-yl)- 1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
CA3199568A1 (en) * 2020-12-04 2022-06-09 Reistone Biopharma Company Limited Small molecule inhibitor of cathepsin c and medicinal use thereof
WO2023243601A1 (ja) * 2022-06-13 2023-12-21 モジュラス株式会社 アザシクロアルキルカルボニル環状アミン化合物
EP4551554A1 (en) 2022-07-06 2025-05-14 Chiesi Farmaceutici S.p.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
CN119948034A (zh) * 2022-10-26 2025-05-06 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
WO2025214464A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Crystalline forms of (s) -n- (1-cyano-2- (2-fluoro-4- (1' - (oxetan-3-yl) -3h-spiro [isobenzofuran-1, 4' -piperidin] -6-yl) phenyl) ethyl) -2-azabicyclo [2.2.2] octane-1-carboxamide

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125727A (en) 1976-10-18 1978-11-14 American Cyanamid Company Method of preparing imidazoisoindolediones
GB8922355D0 (en) 1989-10-04 1989-11-22 British Telecomm Sealing gland
GEP20012487B (en) 1998-09-16 2001-07-25 Merab Lomia Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
WO2002069901A2 (en) 2001-03-02 2002-09-12 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
JP2006527704A (ja) 2003-06-18 2006-12-07 プロザイメックス・アクティーゼルスカブ プロテアーゼ阻害剤
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
US20060223846A1 (en) 2005-03-08 2006-10-05 Dyatkin Alexey B Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
MX2008014800A (es) * 2006-06-01 2008-12-02 Sanofi Aventis Nitrilos espirociclicos como inhibidores de proteasa.
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5240201B2 (ja) 2007-10-12 2013-07-17 富士通株式会社 Ｉｐ電話自動試験システム及び方法
WO2009074829A1 (en) 2007-12-12 2009-06-18 Astrazeneca Ab Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
EA201190235A1 (ru) 2009-05-07 2012-05-30 Астразенека Аб Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
WO2010142985A1 (en) 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
CN104379559B (zh) 2012-04-27 2016-11-09 葛兰素集团有限公司 化合物
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP2900666B1 (en) 2012-09-28 2020-11-04 Cancer Research Technology Limited Azaquinazoline inhibitors of atypical protein kinase c
JP2015533134A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 錠剤の機械的安定性に適切な少なくとも１種の水和物形成活性物質及び／又はアジュバントを含有する機械的に安定な錠剤、特にアルギニン含有錠剤の製造における選択的に水分調整された打錠材料の使用
SG10201705989YA (en) 2012-10-15 2017-08-30 Epizyme Inc Substituted benzene compounds
ME02794B (me) 2012-10-16 2018-01-20 Janssen Pharmaceutica Nv Metilen vezani hinolinil modulatori ror-gama-t
US9181271B2 (en) 2012-11-01 2015-11-10 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
ES2718495T3 (es) 2012-12-21 2019-07-02 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
PE20151280A1 (es) 2012-12-21 2015-09-12 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones
EA201591051A1 (ru) 2013-02-08 2016-06-30 Селджен Авиломикс Рисерч, Инк. Ингибиторы erk и варианты их применения
WO2014140075A1 (en) * 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
GEP201706699B (en) 2013-03-14 2017-07-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2970252B1 (en) * 2013-03-14 2020-06-03 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
BR112015022588A2 (pt) 2013-03-14 2017-07-18 Newlink Genetics Corp composto, composição farmacêutica, e, método para tratamento de imunossupressão em um indivíduo
US10596332B2 (en) * 2014-04-29 2020-03-24 Shl Medical Ag Device for adjusting needle insertion depth
EP3164272A1 (en) 2014-07-03 2017-05-10 Bridgestone Americas Tire Operations, LLC Sidewall decoration on rim guard
TW201625591A (zh) 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN108047240B (zh) * 2014-09-12 2020-08-04 勃林格殷格翰国际有限公司 组织蛋白酶c的螺环化合物抑制剂
ES2705623T3 (es) 2014-09-12 2019-03-26 Glaxosmithkline Ip No 2 Ltd Derivados de tetrahidroquinolina como inhibidores del bromodominio

Also Published As

Publication number Publication date
MX2019009695A (es) 2019-10-07
JP2018044011A (ja) 2018-03-22
CA2960916C (en) 2023-03-07
JP2017526716A (ja) 2017-09-14
PL3191487T3 (pl) 2020-03-31
CN108047240B (zh) 2020-08-04
PE20170438A1 (es) 2017-04-28
US20160075704A1 (en) 2016-03-17
SI3191487T1 (sl) 2019-12-31
EP3511331A1 (en) 2019-07-17
CO2017002268A2 (es) 2017-06-20
TW201625647A (zh) 2016-07-16
MX378099B (es) 2025-03-10
UA118610C2 (uk) 2019-02-11
JP6360961B2 (ja) 2018-07-18
US20170073352A1 (en) 2017-03-16
CY1123033T1 (el) 2021-10-29
CL2017000432A1 (es) 2017-10-20
HK1255362A1 (zh) 2019-08-16
EA201790576A1 (ru) 2017-08-31
DK3191487T3 (da) 2019-10-28
NZ728684A (en) 2022-09-30
MX2017003156A (es) 2017-05-23
AP2017009733A0 (en) 2017-02-28
HUE047208T2 (hu) 2020-04-28
CA2960916A1 (en) 2016-03-17
RS59444B1 (sr) 2019-11-29
PH12017500453B1 (en) 2021-08-06
BR112017003433A2 (pt) 2017-11-28
AU2015314355B2 (en) 2019-06-20
PH12017500453A1 (en) 2017-07-31
SA517381064B1 (ar) 2021-02-07
MX367316B (es) 2019-08-15
HRP20191756T1 (hr) 2019-12-27
US9540373B2 (en) 2017-01-10
CN108047240A (zh) 2018-05-18
KR20170054489A (ko) 2017-05-17
USRE47636E1 (en) 2019-10-08
AU2015314355A1 (en) 2017-02-16
PT3191487T (pt) 2019-11-18
SG11201701633SA (en) 2017-03-30
EP3191487A1 (en) 2017-07-19
EA031376B1 (ru) 2018-12-28
BR112017003433B1 (pt) 2023-11-14
LT3191487T (lt) 2019-10-10
EP3191487B1 (en) 2019-08-07
WO2016038007A1 (en) 2016-03-17
KR102510588B1 (ko) 2023-03-17
US9879026B2 (en) 2018-01-30
IL250262A0 (en) 2017-03-30
TWI687424B (zh) 2020-03-11
IL250262B (en) 2020-03-31
CN107074870B (zh) 2019-07-12
CN107074870A (zh) 2017-08-18
MY188382A (en) 2021-12-07

Similar Documents

Publication Publication Date Title
ES2749009T3 (es) Inhibidores espirocíclicos de Catepsina C
ES2845473T3 (es) (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
US8889708B2 (en) Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
US8877775B2 (en) Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
US8871783B2 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin C
CA2848929A1 (en) Substituted n- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin c
HK1234043B (en) Spirocyclic inhibitors of cathepsin c
HK1234043A1 (en) Spirocyclic inhibitors of cathepsin c